| ²é¿´: 718 | »Ø¸´: 3 | ||||
zwmaxmÒø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
Ĭ¿ËË÷ÒýCASºÅ: 70-00-8 ÒÑÓÐ1È˲ÎÓë
|
| Ĭ¿ËË÷ÒýCASºÅ:70-00-8£¬Ð»Ð»ÁË |
» ²ÂÄãϲ»¶
µÚ4ÄêÁË£¬ÂíÉÏ40ÁË£¬¿ÉÄÜÎÒÓë¹ú»ùȷʵÎÞÔµ°É¡£¡£¡£
ÒѾÓÐ12È˻ظ´
аæscifinder
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ202È˻ظ´
°²½ÝÂ×ÒºÏàÉ«Æ×ÖùÓë·½·¨¿ª·¢Ö¸ÄÏ
ÒѾÓÐ4È˻ظ´
2026ÄêÉ격ҩѧרҵ
ÒѾÓÐ1È˻ظ´
2026ÉêÇ뿼ºË²©Ê¿×Ô¼ö-µ°°×ÖÊ×éѧ/AI/Ò©ÎïÉè¼Æ/AIDD/»¯Ñ§ÉúÎïѧ
ÒѾÓÐ1È˻ظ´
ҩѧר˶É격
ÒѾÓÐ3È˻ظ´
ÖйúÒ½Ò©ÐÐÒµ·¢Õ¹ÏÖ×´£º±ê×¼Æ·ÍÆ¶¯Ò©Æ·¼ì²âˮƽÌáÉý
ÒѾÓÐ1È˻ظ´
±ê׼ƷµÄ´¿¶È¶ÔÓÚÒ©Æ·ÖÊÁ¿µÄÓ°ÏìÓжà´ó£¿
ÒѾÓÐ0È˻ظ´
ÈçºÎÖÆ±¸·ûºÏ¼¼ÊõÒªÇóµÄÒ©Æ·±ê׼Ʒ£¿
ÒѾÓÐ0È˻ظ´
kk1424
Ö÷¹ÜÇø³¤ (ÖøÃûдÊÖ)
ÖÐÒ©Ñо¿Õß
-

ר¼Ò¾Ñé: +2 - DRDEPI: 11
- Ó¦Öú: 249 (´óѧÉú)
- ¹ó±ö: 7.374
- ½ð±Ò: 24151.6
- É¢½ð: 14951
- ºì»¨: 536
- ɳ·¢: 16
- Ìû×Ó: 2401
- ÔÚÏß: 6221.1Сʱ
- ³æºÅ: 1325536
- ×¢²á: 2011-06-17
- ÐÔ±ð: GG
- רҵ: Ò©Îï¶¾Àí
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
zwmaxm: ½ð±Ò+10, ¡ïÓаïÖú 2016-07-26 15:21:45
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
zwmaxm: ½ð±Ò+10, ¡ïÓаïÖú 2016-07-26 15:21:45
|
Trifluridine Structural Formula Vector Image Title: Trifluridine CAS Registry Number: 70-00-8 CAS Name: a,a,a-Trifluorothymidine Additional Names: 2¡é-deoxy-5-(trifluoromethyl)uridine; 5-(trifluoromethyl)-2¡é-deoxyuridine; F3TDR Manufacturers' Codes: NSC-75520 Trademarks: TFT Thilo (Alcon-Thilo); Virophta (Dulcis); Viroptic (Burroughs Wellcome) Molecular Formula: C10H11F3N2O5 Molecular Weight: 296.20 Percent Composition: C 40.55%, H 3.74%, F 19.24%, N 9.46%, O 27.01% Literature References: Prepn: C. Heidelberger et al., J. Am. Chem. Soc. 84, 3597 (1962); eidem, J. Med. Chem. 7, 1 (1964); C. Heidelberger, US 3201387 (1965 to U.S. Dept. HEW). Crystal structure: A. H. Tench, Diss. Abstr. Int. B 33, 3587 (1973). NMR study: R. J. Cushley et al., J. Am. Chem. Soc. 90, 709 (1968). Metabolism: D. L. Dexter et al., Cancer Res. 32, 247 (1972); W. J. O'Brien, H. F. Edelhauser, Invest. Ophthalmol. Visual Sci. 16, 1093 (1977). Pharmacodynamics: B. L. Wigdahl, J. R. Parkhurst, Antimicrob. Agents Chemother. 14, 470 (1978); G. J. Smith et al., Biochem. Biophys. Res. Commun. 83, 1538 (1978). Teratogenicity study: M. Itoi et al., Arch. Ophthalmol. 93, 46 (1975). Cytotoxicity and mutagenicity study: E. Huberman, C. Heidelberger, Mutat. Res. 14, 130 (1972). Clinical studies: H. E. Kaufman, Invest. Ophthalmol. Visual Sci. 17, 941 (1978); R. A. Hyndiuk et al., Arch. Ophthalmol. 96, 1839 (1978). Review of mechanism of antiviral activity: C. Heidelberger, Ann. N.Y. Acad. Sci. 255, 317 (1975). Review of pharmacology and therapeutic use: A. A. Carmine et al., Drugs 23, 329-353 (1982). Properties: Cryst from ethyl acetate, mp 186-189¡ã. uv max (0.1N HCl): 260 nm (e 9960); (0.1N NaOH): 260 nm (e 6590). Melting point: mp 186-189¡ã Absorption maximum: uv max (0.1N HCl): 260 nm (e 9960); (0.1N NaOH): 260 nm (e 6590) Therap-Cat: Antiviral (ophthalmic). Keywords: Antiviral; Purines/Pyrimidinones. |

2Â¥2016-07-26 14:56:51
zwmaxm
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 269
- Ìû×Ó: 112
- ÔÚÏß: 45Сʱ
- ³æºÅ: 1778938
- ×¢²á: 2012-04-25
- רҵ: Ò©Îﻯѧ
3Â¥2016-07-26 15:05:02
kk1424
Ö÷¹ÜÇø³¤ (ÖøÃûдÊÖ)
ÖÐÒ©Ñо¿Õß
-

ר¼Ò¾Ñé: +2 - DRDEPI: 11
- Ó¦Öú: 249 (´óѧÉú)
- ¹ó±ö: 7.374
- ½ð±Ò: 24151.6
- É¢½ð: 14951
- ºì»¨: 536
- ɳ·¢: 16
- Ìû×Ó: 2401
- ÔÚÏß: 6221.1Сʱ
- ³æºÅ: 1325536
- ×¢²á: 2011-06-17
- ÐÔ±ð: GG
- רҵ: Ò©Îï¶¾Àí
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø

4Â¥2016-07-26 15:16:23













»Ø¸´´ËÂ¥